ToxiPharm LLC

ToxSignal

Clinical Toxicology Intelligence

Issue

#15

August 2026

The New Federal "Treatment First" Toolkit Does Not Resolve Where MOUD Fits.

On August 12, HHS, ONDCP, and HUD jointly launched a "Treatment First" toolkit aimed at people experiencing homelessness and addiction. The $100 million initiative prioritizes treatment engagement over housing-first models, centers faith-based and abstinence-oriented programs, and explicitly rejects harm reduction framing. Within two days, the Drug Policy Alliance and disability rights organizations including DREDF had issued sharp statements condemning the approach.

The ambiguity at the center of the toolkit is its language around "evidence-based treatment." The document endorses it while simultaneously rejecting harm reduction. For patients receiving methadone through an OTP or buprenorphine from an outpatient prescriber, that creates a policy gap: methadone and buprenorphine are the most rigorously studied interventions in addiction medicine, but they are routinely excluded from programs that label themselves abstinence-oriented. Whether "Treatment First" in federal grant language will be interpreted to include or exclude MOUD access for people experiencing homelessness is not yet answered by the toolkit itself.

The downstream implications for OTPs and CTCs are indirect but real: if federal homeless services funding increasingly flows through "Treatment First" frameworks, OTPs may face referral partners who are not MOUD-neutral or who actively discourage medication continuation. Sources: HHS announcement; DPA statement; STAT coverage.

42 CFR Part 8 / Methadone Flexibilities

Two Years After the Overhaul, Only 37% of OTPs Adopted All of the New Flexibilities.

STAT News published a major feature August 14 examining whether OTPs have actually changed since the 2024 methadone rules overhaul. The piece pairs with SAMHSA adoption data showing that roughly 70% of OTPs adopted most of the liberalized regulations but only 37% adopted all of them. The two pressure points are take-home flexibility and decoupling counseling from medication dispensing. Both remain areas where program culture has not caught up to what the rules now allow.

A Pew analysis published August 7 adds useful context: expanded take-home methadone has not increased diversion, and methadone-involved mortality declined from 2020 to 2024. The adoption gap is not being driven by evidence of harm from the flexibilities themselves.

Sources: STAT News (Aug 14); ADAW/SAMHSA adoption data; Pew (Aug 7)

Drug Safety Signal / OTP

Synthetic Cannabinoids May Lower the Fatal Methadone Concentration Threshold Via Additive QT Effects.

A signal-detection study published in British Journal of Pharmacology (Rock et al.) analyzed UK substance-use mortality data and found that in cases where both methadone and synthetic cannabinoid receptor agonists (SCRAs) were detected, the median fatal methadone concentration was significantly lower than in methadone-only cases. In isolated-heart experiments, 5F-ADB potentiated methadone-induced QTc prolongation. SCRAs are not detected by standard urine drug testing panels. For OTPs: a patient with an elevated or borderline QTc on methadone who is also using a synthetic cannabinoid outside the panel window may carry higher cardiac risk than the UDT result suggests. Source: doi:10.1111/bph.70635

J Med Internet Res  ·  Prospective Cohort  ·  August 2026

Telehealth-Only Buprenorphine: 71% Retained at 6 Months Across 22,064 Patients.

Monico et al. analyzed a multistate retrospective cohort from Boulder Care (a telehealth-only buprenorphine program) and found 6-month retention of 71% — well above most published benchmarks for buprenorphine retention in traditional outpatient settings. The study includes 22,064 patients across multiple states, making it one of the largest telehealth buprenorphine datasets published to date. The strongest predictor of retention was prior buprenorphine exposure: patients with prior exposure showed 70.4% retention at month 6 versus 52.0% for those without it. doi:10.2196/100527

Contemp Clin Trials  ·  Trial Design  ·  August 2026

GLP-1 Agonists Move From Observational Signal to RCT: NIDA CTN Launches TAB Trial.

Winhusen et al. published the design paper for TAB (Tirzepatide as an Adjunct to Buprenorphine), the first randomized controlled trial of a GLP-1/GIP dual agonist added to buprenorphine for OUD (approximately 310 adults, 9 sites; primary outcome 6-month retention). Patients and prescribers are already asking whether GLP-1s help with cravings; the honest answer is now "we are finding out formally." Cite this trial when the question comes up. doi:10.1016/j.cct.2026.108437

From Bill

"Evidence-based treatment" and "harm reduction" are not opposites. Buprenorphine and methadone are both evidence-based treatments, and they are also harm reduction. When policy language draws a boundary between the two, it is worth asking exactly who ends up on which side of it. The Treatment First toolkit does not answer that question. The implementation guidance will.

Dr. William Bundy Jr., PharmD  ·  ToxiPharm LLC

Tox Pearl #15 is out.

Early-stage xylazine wounds present as papules, pustules, and blistering before necrosis sets in. The window for intervention is before the late presentation. This Pearl covers how to recognize the early signs and what to do with them. Free one-page clinical reference at toxipharm.org.

Questions about a drug test result? Consulting on an OTP or drug court program?

Single-drug deep dives for frontline clinicians and testing programs.